Professional Title：Full Professor，
Doctoral Supervisor
Office: North side, 9th floor, new building of School of Basic Medical Sciences
Research Interests:
1- Neuropeptide & Pain
2- Development of novel neuropeptide drugs
Education/Training:
2002 School of Life Science, Lanzhou University B.Sc. in Biochemistry
2007 School of Life Science, Lanzhou University Ph.D. in Biochemistry and Molecular Biology
2014.1- 2014.12 Visiting Scholar in Duke University Medical Center in the Department of Neurology (Lab of Wolfgang Liedtke)
2007- 2011 Lectuer Lanzhou University, China,
2011- 2014 Associate Professor, Master's Supervisor School of Basic Medical Sciences, Lanzhou University
2014- Present Professor, Doctoral Supervisor School of Basic Medical Sciences, Lanzhou University
2014- Present Head of Institute of Physiology& Psychology School of Basic Medical Sciences, Lanzhou University
2019- Present Deputy Dean of School of Basic Medical Sciences, Lanzhou University
Awards&Honors:
1. 2013, the program of New Century Excellent Talents in University
2. 2016, the second prizes of National Award for Technological Invention (No. 3)
3. 2016, the first prizes of the Ministry of Education Award for science and technology progress (No. 5)
4. 2013, the first prizes of China Pharmaceutical Association Award for science and technology (No. 2)
5. 2012, the first prizes of Gansu Provincial Award for technology invention (No. 2)
Projects:
1. National Natural Science Foundation of China (81973159), The Orally Active Multi-target Cyclic Peptides for Opioid and Neuropeptide FF Receptors: Design, Synthesis and Pharmacological Characterization, 2020.1-2023.12
2. National Natural Science Foundation of China (81673282), The chemical building of the multi-target compounds towards cannabinoid/neuropeptide FF receptors basing on neureopeptides and the studies of their no-tolerance forming antinociception, 2017.1-2020.12
3. Fundamental Research Funds for the Central Universities (lzujbky-2018-ot02), Development of novel neuropeptide drugs, 2018.1-2019.12
4. National Natural Science Foundation of China (81273355), Novel bifunctional ligands for opioid and NPFF receptors: synthesis and characterization of its nontolerance-forming analgesia, 2013.1-2016.12
5. Fundamental Research Funds for the Central Universities (lzujbky-2017-12), The regulatory effect and molecular mechanism of opioid peptides on inflammatory and neuropathic pain, 2017.1-2018.12
6. New Century Excellent Talents in University(NCET-13-0257), 2014.1-2016.12
7. Fundamental Research Funds for the Central Universities (lzujbky-2016-58), The effect and its mechanism of neuropeptide FF system on itch behavior, 2016.1-2017.6
8. Fundamental Research Funds for the Central Universities (lzujbky-2014-k02), Analgesic action and its mechanism of endogenous cannabinoid peptides, and their application in the development of novel analgesic drugs, 2014.1-2015.12
9. Natural Science Foundation of Gansu Province (1208RJYA001), Building of chimeric peptides based on neuropeptide FF and opioid peptides and their application in the development of novel analgesic drugs, 2013.1-2015.12
10. National Natural Science Foundation of China (20902041), Design and synthesis of the novel highly selective ligands of NPFF1 and NPFF2 receptors by introducing the environment-sensitive fluorescent amino acids, 2013.1-2016.12
11. The Specialized Research Fund for the Doctoral Program in Higher Education Institutions (200807301028), Study on the structure-activity relationship and biological activity of 26RFa, a novel member of RFa peptide family, 2009.1-2011.12
Publications:
1. Xu B, Xiao J, Xu KT, Zhang QQ, Chen D, Zhang R, Zhang MN, Zhu HW, Niu JD, Zheng T, Li N, Zhang XY, Fang Q*. VF-13, a chimeric peptide of VD-hemopressin(α) and neuropeptide VF, produces potent antinociception with reduced cannabinoid-related side effects. Neuropharmacology 2020; 175: 108178. ( IF2018 = 4.367)
2. Zhang R, Xu B, Zhang QQ, Chen D, Zhang MN, Zhao GH, Xu KT, Xiao J, Zhu HW, Niu JD, Li N*, Fang Q*. Spinal administration of the multi-functional opioid/neuropeptide FF agonist BN-9 produced potent antinociception without development of tolerance and opioid-induced hyperalgesia. European Journal of Pharmacology. 2020; 880: 173169. (IF2018 = 3.170)
3. Xu B, Guo YY, Zhang MN, Zhang R, Chen D, Zhang QQ, Xiao J, Xu KT, Li N, Qiu Y, Zhu HW, Niu JD, Zhang XY*, Fang Q*. Central and peripheral modulation of gastrointestinal transit in mice by DN-9, a multifunctional opioid/NPFF receptor agonist. Neurogastroenterology & Motility. 2020; dio: 10.1111/nmo.13848. (IF2018 = 3.803)
4. Wang ZL, Xu B, Jiang CY, Zhang T, Zhang MN, Li N, Zhang QQ, Xu KT, Chen D, Xiao J, Fang Q*. Spinal DN-9, a peptidic multifunctional opioid/neuropeptide FF agonist produced potent nontolerance forming analgesia with limited side effects. Journal of Pain. 2019; doi: 10.1016/j.jpain.2019.08.016. (SCI, IF2018 = 5.424)
5. Xu B, Zhang MN, Shi XR, Zhang R, Chen D, Chen Y, Wang ZL, Qiu Y, Zhang T, Xu KT, Zhang XY, Liedtke W*, Wang R*, Fang Q*. The multifunctional peptide DN-9 produced peripherally acting antinociception in inflammatory and neuropathic pain via mu and kappa opioid receptors. British Journal of Pharmacology. 2020; 177: 93-109. (SCI, IF2018 = 6.583, Top Journal)
6. Zhang T, Han Z, Shi X, Zhao W, Wang Z, Zhang R, Xu B, Zhang M, Zhang Q, Xiao J, Zhu H, Zheng T, Fang Q*. Discovery of two novel branched peptidomimetics containing endomorphin-2 and RF9 pharmacophores: Synthesis and neuropharmacological evaluation. Bioorganic & Medicinal Chemistry. 2019; 27: 630-643. (SCI, IF2018 = 2.802)
7. Zhang T1, Zhang N1, Zhang R, Zhao WD, Chen Y, Wang ZL, Xu B, Zhang MN, Shi XR, Zhang QQ, Guo YY, Xiao J, Chen D, Fang Q*. Preemptive intrathecal administration of endomorphins relieves inflammatory pain in male mice via inhibition of p38 MAPK signaling and regulation of inflammatory cytokines. Journal of Neuroinflammation. 2018; 15: 320. (SCI, IF2018 = 5.700) (1: authors contributed equally to this work)
8. Zhang T, Zhao WD, Zhang MN, Xu B, Shi XR, Zhang QQ, Guo YY, Xiao J, Chen D, Zheng T, Fang Q*. Analgesic activities of the mixed opioid and NPFF receptors agonist DN-9 in a mouse model of formalin-induced orofacial inflammatory pain. Peptides. 2018; 110C: 30-39. (SCI, IF2018 = 2.659)
9. Chen C
1,
Xu B
1, Shi XR, Zhang MN, Zhang QQ, Zhang T, Zhao WD, Zhang R, Wang ZL,
Fang Q*. GpTx-1 and [Ala
5, Phe
6, Leu
26, Arg
28]GpTx-1, two peptide NaV1.7 inhibitors: analgesic and tolerance properties at the spinal level.
British Journal of Pharmacology. 2018; 175(20): 3911-3927 (SCI, IF
2018 =
6.583, Top Journal) (
1: authors contributed equally to this work)
10. Li N, Han ZL, Xu B, Zhang MN, Zhang T, Shi XR, Zhao WD, Guo YY, Zhang QQ, Fang Q*. Systemic administration of the bifunctional opioid/neuropeptide FF receptors agonist BN-9 produced peripheral antinociception in preclinical mouse models of pain. European Journal of Pharmacology. 2018; 837: 53-63. (SCI, IF2018 = 3.170)
11. Wang P, Zheng T,
Zhang MN, Xu B, Zhang R, Zhang T, Zhao WD, Shi XR,
Zhang QQ,
Fang Q*.
Antinociceptive effects of the endogenous cannabinoid peptide agonist VD-hemopressin(β) in mice.
Brain Research Bulletin. 2018; 139:48-55. (SCI, IF
2018 = 3.103)
12. Zheng T
1, Zhang R
1, Zhang T, Zhang MN, Xu B, Song JJ, Li N, Tang HH, Wang P, Wang R*,
Fang Q*. CB1 cannabinoid receptor agonist mouse VD-hemopressin(α) produced supraspinal analgesic activity in the preclinical models of pain.
Brain Research. 2018; 1680: 155-164. (SCI, IF
2018 = 2.929)
13. Zhang R, Xu B, Zhang MN, Zhang T, Wang ZL, Zhao G, Zhao GH, Li N,
Fang Q*, Wang R
*. Peripheral and central sites of action for anti-allodynic activity induced by the bifunctional opioid/NPFF receptors agonist BN-9 in inflammatory pain model.
European Journal of Pharmacology. 2017; 813:122-129. (SCI, IF
2018 = 3.170)
14. Zheng T, Zhang T, Zhang R, Wang ZL, Han ZL, Li N, Li XH, Zhang MN, Xu B, Yang XL,
Fang Q*, Wang R
*. Pharmacological characterization of rat VD-hemopressin(α), an α-hemoglobinderived peptide exhibiting cannabinoid agonist-like effects in mice.
Neuropeptides 2017, 63: 83-90. (SCI, IF
2018 =
2.407)
15. Wang ZL, Pan JX, Song JJ, Tang HH, Yu HP, Li XH, Li N, Zhang T, Zhang R, Xu B, Zhang MN,
Fang Q*, Wang R
*. Structure-based optimization of multifunctional agonists for opioid and neuropeptide FF receptors with potent non-tolerance forming analgesic activities.
Journal of Medicinal Chemistry. 2016; 59(22):10198-10208. (SCI, IF
2018 = 6.
054, Top Journal)
16. Yu HP, Zhang N, Zhang T, Wang ZL, Li N, Tang HH, Zhang R, Zhang MN, Xu B,
Fang Q*, Wang R
*. Activation of NPFF2 receptor stimulates neurite outgrowth in Neuro 2A cells through activation of ERK signaling pathway.
Peptides. 2016; 86: 24-32. (SCI, IF
2018 = 2.659)
17. Li N
1,
Han ZL
1, Wang ZL, Xing YH, Sun YL, Li XH, Song JJ, Zhang T, Zhang R, Zhang MN, Xu B,
Fang Q*, Wang R
*.
BN-9, a chimeric peptide with mixed opioid and NPFF receptors agonistic properties, produces nontolerance-forming antinociception in mice. British Journal of Pharmacology. 2016; 173(11): 1864-1880. (SCI, IF
2018 = 6.583, Top Journal) (
1: authors contributed equally to this work)
18. Wang ZL
1, Li N
1, Wang P, Tang HH, Han ZL, Song JJ, Li XH, Yu HP, Zhang T, Zhang R, Xu B, Zhang MN,
Fang Q*, Wang R
*.
Pharmacological characterization of EN-9, a novel chimeric peptide of endomorphin-2 and neuropeptide FF that produces potent antinociceptive activity and limited tolerance. Neuropharmacology. 2016; 108: 364-372 (SCI, IF
2018 =
4.367，Top Journal) (
1: authors contributed equally to this work)
21. Zhang XY, Chen Y, Li Lin, Qiao H, Wang R, Ni JM *, You JQ, Ma KK, Fan CC, Fang Q. Development and validation of a reversed phase liquid chromatographic method with fluorescence detection for the pharmacokinetic study of a new chimeric peptide. Analytical Methods. 2016; 8(12): 2620-2627. (SCI, IF2018 = 2.378)
22. Pan JX
1, Wang ZL
1, Li N, Zhang N, Wang P, Tang HH, Zhang T, Yu HP, Zhang R, Zheng T,
Fang Q*, Wang R*.
Effects of neuropeptide FF and related peptides on the antinociceptive activities of VD-hemopressin(α) in naive and cannabinoid-tolerant mice. European Journal of Pharmacology. 2015; 767(C):119-125. (SCI, IF
2018 = 3.170) (
1: authors contributed equally to this work)
23. Han ZL, Wang ZL, Li XH, Li N, Pan JX, Zheng T,
Fang Q*, Wang R*. Neuropeptide VF enhances cannabinoid agonist WIN55,212-2-induced antinociception in mice.
Anesthesia & Analgesia. 2015; 121(5):1360-1368. (SCI, IF
2018 = 3.489)
24. Chen Y, Kanju P
2,
Fang Q 2, Lee SH, Parekh PK, Lee W, Moore C, Brenner D, Gereau RW 4th, Wang F, Liedtke W
*. TRPV4 is necessary for trigeminal irritant pain and functions as a cellular formalin receptor.
Pain. 2014; 155(12):2662-72. (SCI, IF
2018 = 6.029, 医学2区) (
2: authors contributed equally to this work)
25. Han ZL
1,
Fang Q1, Wang ZL, Li XH, Li N, Chang XM, Pan JX, Tang HZ, Wang R
*. Antinociceptive effects of central administration of the endogenous CB1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)] , a N-terminally extended hemopressin peptide.
Journal of Pharmacology and Experimental Therapeutics. 2014; 348(2): 316-323. (SCI, IF
2018 = 3.615，Top Journal) (
1: authors contributed equally to this work)
26. Wang ZL
1,
Fang Q 1, Han ZL, Pan JX, Li XH, Li N, Tang HH, Wang P, Zheng T, Chang XM, Wang R*. Opposite Effects of Neuropeptide FF on Central Antinociception Induced by Endomorphin-1 and Endomorphin-2 in Mice.
PLoS One. 2014; 9(8): e103773. (SCI, IF
2018 = 2.776)
(1: authors contributed equally to this work)27. Pan JX, Wang ZL, Li N, Han ZL, Li XH, Tang HH, Wang P, Zheng T, Fang Q*, Wang R*. Analgesic tolerance and cross-tolerance to the cannabinoid receptors ligands hemopressin, VD-hemopressin(α) and WIN55,212-2 at the supraspinal level in mice. Neuroscience Letters. 2014; 578: 187-191. (SCI, IF2018 = 2.173)
28. Li XH1, Li N1, Wang ZL, Pan JX, Han ZL, Chang XM, Tang HH, Wang P, Wang R*, Fang Q*. The hypotensive effect of intrathecally injected (m)VD-hemopressin(α) in urethane-anesthetized rats. Peptides. 2014; 56(C): 45-51. (SCI, IF2018 = 2.659)
29. Han ZL, Wang ZL, Tang HZ, Li N,
Fang Q*, Li XH, Yang XL, Zhang XY, Wang R
*. Neuropeptide FF attenuates the acquisition and the expression of conditioned place aversion to endomorphin-2 in mice.
Behavioural Brain Research 2013; 248(1):51-56. (SCI, IF
2018 = 2.770)
30. Sun YL, Zhang XY, He N, Sun T, Zhuang Y, Fang Q*, Wang KR, Wang R*. Neuropeptide FF activated ERK and NF kappa B signal pathways in differentiated SH-SY5Y cells. Peptides 2012; 38(1):110-117. (SCI, IF2018 = 2.659)
31. Li N 1, Han ZL 1, Fang Q*, Wang ZL, Tang HZ, Ren H, Wang R*. Neuropeptide FF and related peptides attenuates warm-, but not cold-water swim stress-induced analgesia in mice. Behavioural Brain Research 2012; 233(2): 428-433. (SCI, IF2018 = 2.770)
32.
Fang Q, Han ZL, Li N, Wang ZL, He N, Wang R
*. Effects of neuropeptide FF system on CB
1 and CB
2 receptors mediated antinociception in mice.
Neuropharmacology 2012; 62 (2): 855-864. (SCI, IF
2018 = 4.367, Top Journal)
33.
Fang Q 1, Jiang TN
1, Li N, Han ZL, Wang R
*. Central administration of neuropeptide FF and related peptides attenuate systemic morphine analgesia in mice.
Protein & Peptide Letters 2011; 18(4): 403-409. (SCI, IF
2018 = 1.168) (
1: authors contributed equally to this work)
34.
Fang Q 1, Li N
1, Jiang TN, Liu Q, Li YL, Wang
R
*. Pressor and tachycardic responses to intrathecal administration of Neuropeptide FF in anesthetized rats
. Peptides 2010; 31(4): 683-688.
(SCI, IF2018 = 2.659) (
1: authors contributed equally to this work)
35. Fang Q 1, Liu Q 1, Li N, Jiang TN, Li YL, Yan X, Wang R*. Cardiovascular effects of intravenous administered 26RFa, a novel RF-amide peptide ligand for GPR103, in anaesthetized rats. European Journal of Pharmacology 2009; 621(1-3): 61-66. (SCI, IF2018 = 3.170) (1: authors contributed equally to this work)
36. Fang Q, Wang YQ, He F, Guo J, Guo J, Chen Q, Wang R*. Inhibition of neuropeptide FF (NPFF)-induced hypothermia and anti-morphine analgesia by RF9, a new selective NPFF receptors antagonist. Regulatory Peptides 2008; 147(1-3): 45-51. (SCI, IF2008 = 2.276)
37.
Fang Q, Zhang BZ, Wang R
*. Progress in the structure-activity relationship studies of neuropeptide FF.
Progress in Chemistry 2007; 19: 1977-1985. (SCI, IF
2018 = 0.862, Review, in Chinese)
38. Fang Q, He F, Wang YQ, Guo J, Zhang BZ, Chen Q, Wang R*. Pharmacological effects of the dansylated neuropeptide FF analogues on body temperature and morphine analgesia. Neuropeptides 2007; 41(5): 339-347. (SCI, IF2018 = 2.407)
39. Fang Q, Guo J, He F, Peng YL, Chang M, Wang R*. In vivo inhibition of neuropeptide FF agonism by BIBP3226, an NPY Y1 receptor antagonist. Peptides 2006; 27(9): 2207-2213. (SCI, IF2018 = 2.659)
40. Fang Q, Guo J, Peng YL, Chang M, He F, Chen Q, Wang R*. In vitro and in vivo studies of dansylated compounds, the putative agonists and antagonists on neuropeptide FF receptors. Peptides 2006; 27(6): 1297-1304. (SCI, IF2018 = 2.659)
41. Fang Q, Guo J, Chang M, Chen LX, Chen Q, Wang R*. Neuropeptide FF receptors exert contractile activity via inhibition of nitric oxide release in the mouse distal colon. Peptides 2005; 26(5): 791-797. (SCI, IF2018 = 2.659)
42. Chen LX , Fang Q, Chen Q, Guo J, Wang ZZ, Chen Y, Wang R. Study in vitro and in vivo of nociceptin/orphanin FQ(1-13)NH2 analogues substituting N-Me-Gly for Gly2 or Gly3. Peptides 2004; 25(8): 1349-1354. (SCI, IF2018 = 2.659)
43. Wang YQ, Guo J, Wang SB, Fang Q, He F, Wang R*. Neuropeptide FF receptors antagonist, RF9, attenuates opioid-evoked hypothermia in mice. Peptides 2008; 29(7): 1183-90. (SCI, IF2018 = 2.659)
44. Chen LX, Wang ZZ, Wu H, Fang Q, Chen Y, Guo J, Chen Y, Wang R*. Effects of nociceptin (13-17) in pain modulation at supraspinal level in mice. Neuroscience Letters 2002; 331(2): 95-98. (SCI, IF2018 = 2.173)
45. Wang YQ, Wang SB, Ma JL, Guo J, Fang Q, Sun T, Zhuang Y, Wang R*. Neuropeptide FF receptor antagonist, RF9, attenuates the fever induced by central injection of LPS in mice. Peptides. 2011; 32(4): 702-706. (SCI, IF2018 = 2.659)
46. Sun YL, Zhang XY, Sun T, He N, Li JY, Zhuang Y, Fang Q, Wang R. The anti-inflammatory potential of neuropeptide FF in vitro and in vivo. Peptides 2013; 47:124-132. (SCI, IF2018 = 2.659)
47. Sun YL, Sun T, Zhang XY, He N, Zhuang Y, Li JY, Fang Q, Wang KR, Wang R*. NPFF2 receptor is involved in the modulatory effects of neuropeptide FF for macrophage cell line. Protein & Peptide Letters 2014; 21(5): 490-502. (SCI, IF2018 = 1.168)
